Lighting the way

How watching a baseball game led to a discovery that made laser surgery possible

The concept that revolutionized laser surgery and earned UC Irvine nearly $60 million came to Dr. J. Stuart Nelson in 1992 while he was watching a baseball game.

In the early 1990s, surgeons like Nelson were attempting to adapt laser technology for medical use, and the Beckman Laser Institute & Medical Clinic served as an epicenter for this effort. It was, at the time, the only facility in the world to house basic science and engineering labs and an outpatient clinic under one roof, letting researchers and surgeons quickly translate findings into patient-care breakthroughs.

As medical director of the BLIMC, Nelson had been striving to improve laser treatments for disfiguring vascular birthmarks, such as port-wine stains, in infants and young children. Laser’s utility was limited because its intense light also injured the fragile top layer of skin, causing pain, scarring and pigmentation changes. The challenge was to find a way to protect the outer skin while maximizing the destruction of the deeper blood vessels that create a birthmark.

Nelson and his BLIMC colleagues at the time – postdoctoral researcher Thomas Milner and visiting Norwegian engineer Lars Svaasand – had tried using ice cubes, running cold water and even the application of chilled metal plates to cool the skin’s superficial layer before laser exposure. Unfortunately, all of these methods proved too cumbersome and, more importantly, also cooled the targeted blood vessels, which inhibited the laser’s effectiveness.

“We needed to get something very cold onto the skin surface in perfect thermal contact and then off the skin surface – all within a fraction of a second,” Nelson said. “I remembered what I saw watching a baseball game.”

Over a Friday night dinner at the former Rusty Pelican restaurant in Irvine, he told his colleagues how, when a batter fouled a baseball off his foot or ankle, a trainer would emerge from the dugout and spray ethyl chloride onto the injury site to numb the pain. The three agreed that spray cooling might be effective with lasers if the cryogenic agent evaporated very quickly and, therefore, only affected the topmost layer of skin.

During the weekend, Milner and Svaasand hashed out ideas on how this concept could work; on Monday, they went to Pep Boys and purchased a Toyota Camry fuel injector valve, a hose clamp and air conditioning coolant to build the first prototype of the Dynamic Cooling Device.

To determine the optimal cryogen spurt duration and interval between spurt termination and laser exposure, all three researchers tested the DCD on themselves. “We still have scars on our arms to prove it,” Nelson said.

“It was a fairly simple construction,” said Milner, who is now the Olga Keith Wiess Professor of Surgery and director of the Michael E. DeBakey Center for Nano-Biophotonics at the Baylor College of Medicine in Houston. “That’s the beauty of the invention: It’s so simple and works so well.”

The device is incorporated into the laser’s handpiece and sprays a nonflammable, environmentally compatible freon substitute onto the skin surface, forming a liquid pool with a temperature of -60 degrees Celsius. This pool almost immediately evaporates, and milliseconds later, the skin is exposed to the laser. The process is repeated before each pulse of light.

“Because the spurt durations are so short, the cooling remains confined to the skin’s most superficial layer and does not affect the deeper targeted blood vessels causing the vascular birthmark,” Nelson explained. “This allows much higher laser light dosages to be used, while at the same time minimizing injury to the skin and pain to the patient.”

The DCD was patented in September 1998 and subsequently licensed to Candela Laser Corp. for commercial development and marketing. The patent expired in 2020. It’s now standard on more than 47,000 Candela lasers sold worldwide, as well as on the lasers of other companies around the world.

Between 2001 and 2010, the device was among the 10 top-earning licensed inventions in the University of California system – and in 2005 and 2006, it ranked second and third, respectively. To date, the DCD generated nearly million in royalties for UC Irvine.

“The combination of basic research, engineering and clinical testing that went into the Dynamic Cooling Device is exactly what was envisioned over 30 years ago when the idea of the BLIMC was first conceived,” said Michael Berns, the Arnold & Mabel Beckman Chair in Laser Biomedicine and institute co-founder, to ZotZine in 2011.

While DCD-equipped lasers are utilized for several cosmetic procedures – the removal of unwanted hair, scars and rosacea, for example – Nelson is pleased that his invention primarily benefits individuals born with port-wine stains. At the BLIMC’s world-renowned Vascular Birthmarks & Malformations Diagnostic & Treatment Center, he has handled more than 20,000 such cases.

A surgeon at the Beckman Laser Institute & Medical Clinic treats an 8-month-old’s port-wine stain with a DCD-equipped laser.
A surgeon at the Beckman Laser Institute & Medical Clinic treats an 8-month-old’s port-wine stain with a DCD-equipped laser. Steve Zylius / UC Irvine

“The technology has made possible the early, painless, safe and effective treatment of port-wine stains and other disfiguring vascular birthmarks in infants and young children in ways that Tom, Lars and I could never have imagined,” Nelson said. “That’s what I’m most proud of.”

Updated from the original story published in ZotZine Vol. 4, Iss. 2

Click here to read the full article in UC Irvine News.

Howard Lee selected as Moore Experimental Physics Investigator to develop revolutionary nanoscale electron accelerator

Lee’s research could transform cancer treatment and medical technologies

Tatiana Overly | UC Irvine School of Physical Sciences

Professor Howard Lee in the UC Irvine Department of Physics & Astronomy has been named a 2025 Experimental Physics Investigator by the Gordon and Betty Moore Foundation. The funding will support Lee in advancing groundbreaking research in nanoscale electron acceleration technology.

Lee is developing the world’s first nanoscale electron accelerator by merging advanced nano-optical materials and nanostructures with laser wakefield acceleration. Unlike traditional accelerators such as the Large Hadron Collider that require extensive long well-defined channels, Lee’s apparatus uses nanoscale solid-state materials and high-power ultrafast lasers to accelerate electrons and generate X-rays.

“This award is significant since it allows me to pursue an entirely new research direction not previously explored,” Lee said. “Given the current funding climate, the opportunity to support research with bold new ideas is truly game-changing for my group, allowing us to further advance optical science and technology. I am deeply grateful to the Moore Foundation for their generous support.”

Lee’s work could enable new medical therapies, including laser wakefield accelerator optical fiber endoscope probe and free electron laser devices for next-generation biomedical and imaging technologies. When integrated into optical fibers, these nanoscale accelerators could open transformative biomedical applications, including advanced cancer treatments.

The research has significant implications across multiple scientific disciplines, including nano- and nonlinear optics, plasma physics, particle physics, and biophysics. Beyond its practical applications, the research promises fundamental insights into utilizing nanoscale metasurfaces for particle acceleration and could create an entirely new class of light-matter phenomena.

“The year 2025 is a particularly special one for me, as I was promoted to Full Professor at UC Irvine, elected as an Optica Fellow, and now selected as a Moore Experimental Physicist,” said Lee. “I am deeply grateful to my former postdoc advisor, Harry Atwater at Caltech, and my Ph.D. advisor, Philip Russell at the Max Plank Institute for the Science of Light, for their invaluable guidance throughout my academic journey and for serving as inspiring role models in pursuing optical science and photonic technology as a career.” Lee also thanks UC Irvine and his colleague, Professor Toshiki Tajima, a leading theoretical physicist in laser wakefield acceleration, who first introduced him to this field of research.

The Gordon and Betty Moore Foundation advances scientific discovery, environmental conservation, and the special character of the San Francisco Bay Area. Visit moore.org and follow @MooreFound. 

Click here to read full article on the UC Irvine School of Physical Sciences website.

Advancing Discovery: 2025 Experimental Physics Investigators

The 2025 cohort of Experimental Physics Investigators is a distinguished group of mid-career researchers pushing the boundaries of experimental physics. These 22 new investigators are joining the scientists from three previous cohorts in advancing the frontier of fundamental research in experimental physics. Regarding the magnitude and size of the award, 2024 investigator Shimon Kolkowitz remarked, “this is exactly what we needed to attempt our complex experiments, and it is especially important given the current uncertainties in federal funding in the United States.”

The Experimental Physics Investigators Initiative provides $1.3 million over five years to give these scientists flexibility to accelerate breakthroughs and strengthen the experimental physics community.

“We once again received proposals from amazing mid-career investigators who are taking their research to new levels,” said Theodore Hodapp, program director for the initiative. “We are excited to see them join our existing cohorts of experimental physicists who are pushing the boundaries of our understanding of the universe.”

Among this year’s investigators are:

  • Howard Lee from University of California, Irvine who is building the first nanoscale accelerator capable of producing high-energy electrons, with applications in plasma and particle physics as well as biomedcine.
  • Jaideep Taggart Singh from the Facility for Rare Isotope Beams at Michigan State University who is developing an experimental platform to search for time-reversal-violating forces, potentially explaining why the universe contains more matter than antimatter.
  • Adina Luican-Mayer from University of Illinois Chicago who is studying moiré-induced polarization in atomically thin materials, work that could uncover new phases of matter and enable ultra-compact, energy-efficient electronics.

Cultivating collaborative research environments that welcome all students and promote highly effective research teams is a goal of the initiative. Awardees pursue this goal in different ways. For example, Professor Singh will use part of the funding to design unique trainings for students at the intersection of different disciplines including atomic, molecular, optical and nuclear physics.

“To connect investigators and promote the discovery of new ideas and synergistic collaborations, we bring all cohorts together each year in a relaxed setting,” remarked Catherine Mader, program officer for the initiative. “We have seen numerous new connections form and new research directions pursued by both individuals and groups based on conversations at these gatherings.”

Meet the 2025 Experimental Physics Investigators 

The foundation is now accepting applications for the 2026 cohort of Experimental Physics Investigators. The deadline to apply is October 14, 2025. Apply for the 2026 cohort.

Click here to read full article on the Gordon and Betty Moore Foundation website.

Pioneering Light-Based Innovation: New Faculty Join the Institute

Two distinguished researchers bring cutting-edge expertise in optical diagnostics and computational imaging to advance biomedical applications

UC Irvine Beckman Laser Institute & Medical Clinic welcomes two talented new faculty members whose groundbreaking research in optical technologies promises to revolutionize both clinical diagnostics and neuroscience imaging. Drs. Abraham Qavi and Fei Xia join the institute’s renowned interdisciplinary community, bringing complementary expertise that bridges science, engineering, and medicine.

ABRAHAM QAVI: TRANSFORMING CLINICAL DIAGNOSTICS THROUGH ADVANCED OPTICS

Dr. Abraham Qavi joins the Institute as Assistant Professor in Residence of Pathology and Chemistry, bringing a unique combination of clinical expertise and pioneering research in optical diagnostics. As a board-certified pathologist, Dr. Qavi currently serves multiple leadership roles at UC Irvine Medical Center, including Director of Point of Care Testing, Director of Innovative Laboratory Diagnostics, and Associate Director of Clinical Chemistry.

Revolutionary Diagnostic Technologies

Dr. Qavi’s research program leverages sophisticated optical technologies to address critical gaps in clinical diagnostics. His laboratory specializes in photonic resonators and plasmonic-enhanced sensors—advanced techniques that enable precise control and manipulation of light to dramatically improve diagnostic sensitivity and speed.

“Dr. Qavi’s work represents the future of diagnostic medicine,” states Dr. Bernard Choi, Institute Interim Director. “By harnessing the intrinsic properties of light, his research enables ultrasensitive detection capabilities that could transform how we diagnose and monitor disease.”

Dr. Qavi’s research focuses on two primary technological platforms:

Photonic Resonators: These exquisitely sensitive optical devices exploit light confinement principles to achieve unprecedented detection limits. By trapping light in microscopic cavities, photonic resonators can detect minute changes in their optical environment when target molecules bind to their surfaces. This enables detection of viral particles, proteins, or other biomarkers at concentrations far below what conventional tests can achieve.

Plasmonic Enhancement: Dr. Qavi utilizes the unique optical properties of metallic nanoparticles, particularly gold nanostructures, which can concentrate light into extremely small volumes and amplify optical signals. When light interacts with these specially designed nanoparticles, it creates intense electromagnetic fields that dramatically enhance the detection of nearby molecules.

Clinical Applications and Global Impact

Dr. Qavi’s studies have demonstrated efficacy in rapid viral detection, including filoviruses, such as Ebola, and coronaviruses. His platforms can potentially reduce diagnostic time, while maintaining or exceeding the accuracy of traditional laboratory methods.

This potential extends beyond modern healthcare systems. The low-cost, high-throughput nature of plasmonic sensors makes them particularly valuable for addressing neglected tropical diseases in resource-limited settings, where rapid, accurate diagnosis can be lifesaving.

Dr. Qavi’s research areas include ultrasensitive pathogen detection using photonic resonators, point-of-care diagnostic platforms for global health applications, integration of advanced optics with clinical laboratory workflows and the development of laboratory-developed tests (LDTs) for personalized medicine.

Clinical Foundation

Dr. Qavi earned his medical degree from the University of Illinois College of Medicine in Chicago and completed his residency in clinical pathology at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis. This strong clinical foundation informs his research approach, ensuring that technological innovations address real-world medical needs.

Click here to learn more about Dr. Qavi.

FEI XIA: COMPUTATIONAL PHOTONICS FOR ADVANCED BIOMEDICAL IMAGING

Dr. Fei Xia, Assistant Professor of Electrical Engineering and Computer Science, brings pioneering expertise at the intersection of optics, computation, and neuroscience. Her research centers on developing revolutionary optical systems that image, sense, and process biomedical information through groundbreaking light-based technologies.

Dr. Xia’s research centers on two approaches:

Advanced Optical Systems: Dr. Xia develops sophisticated imaging platforms that can capture biological information across multiple spatial and temporal scales simultaneously. These systems often incorporate adaptive optics, multi-modal detection, and real-time feedback control to optimize image quality for specific applications.

Computational Enhancement: Her laboratory develops machine learning algorithms and signal processing techniques specifically designed to extract maximum information from optical measurements. These computational approaches can reveal patterns and structures that would be invisible to conventional analysis methods.

Precision Imaging for Neuroscience

Dr. Xia’s research program focuses on enhancing imaging precision across spatial (seeing smaller structures) and temporal dimensions (capturing faster processes) to unlock new possibilities in biomedical imaging. Her laboratory is particularly dedicated to brain imaging, recognizing the brain’s critical role as both a regulator of health and the source of human intelligence.

Dr. Xia’s current applications include high-resolution imaging of neural networks in living tissue, real-time monitoring of brain activity during cognitive tasks, early detection of neurodegenerative diseases, and the development of precision tools for neurosurgical planning.

“Through the strategic co-design of hardware and software solutions, Dr. Xia addresses complex biomedical challenges and advances our understanding of living biological systems,” states Dr. Choi. “Her work drives the development of more precise diagnostic tools and discovery platforms that advance both neuroscience research and neurological medicine.”

Global Research Perspective

Dr. Xia’s contributions have earned multiple prestigious awards, including the 2024 Rising Star in Light Award and 2023 Optica Foundation Challenge Award, recognizing her as a leader in the next generation of optical scientists.

Dr. Xia brings a strong international research background, having completed her Ph.D. at Cornell University and postdoctoral research at École Normale Supérieure (ENS) in Paris, France. Her diverse educational experience across three continents – undergraduate studies in China, doctoral work in the USA, and postdoctoral research in France – provides a unique global perspective.

Click here to learn more about Dr. Xia.

LOOKING FORWARD

Drs. Qavi and Xia’s work promises to advance the frontiers of optical technologies in biomedicine. From revolutionizing point-of-care diagnostics to unlocking new insights into brain function, their research represents the cutting-edge of light-based innovation to impact human health.

Beckman Laser Institute Receives Grant to Expand STEM Excellence

ACES Program Creates Pipeline for High-Achieving HBCU Students in Graduate Research

UC Irvine Beckman Laser Institute & Medical Clinic has been awarded a $159,400 grant from the University of California Office of the President’s (UCOP) Historically Black Colleges and Universities (HBCU) Initiative. This funding will support the Access to Careers in Engineering and Sciences (ACES) program, an intensive eight-week summer program that opens doors for talented HBCU students in STEM fields.

ACES impacts students’ academic futures by immersing high-achieving undergraduates in cutting-edge research at UC Irvine – one of the nation’s premier research institutions. Participants gain hands-on experience in biomedical engineering, biophotonics, and related STEM disciplines while working alongside distinguished faculty and graduate student mentors.

The program goes beyond laboratory work, offering comprehensive preparation for graduate school through targeted workshops and providing insights into both academic and industry career paths. This holistic approach ensures students leave with both technical skills and strategic knowledge.

“ACES represents our commitment to providing transformative opportunities for exceptional HBCU students in STEM,” said Dr. Eric Potma, Director of UC Irvine’s ACES program. “Through ACES, we are not just introducing students to research possibilities – we are helping to shape the next generation of scientific leaders.”

The numbers tell a compelling story. Over seven years, ACES has created a robust pipeline to graduate education: 11 program alumni have entered UC STEM Ph.D. programs, with nine choosing UC Irvine specifically. An additional 27 ACES graduates have enrolled in graduate programs nationwide, demonstrating the program’s effectiveness in preparing students for advanced study.

This success reflects the broader impact of the UC-HBCU Initiative, which has hosted 994 scholars across all ten UC campuses during its first decade. The initiative’s investment has yielded remarkable results: 82 Ph.D. students currently enrolled at UC institutions and 43 Ph.D. graduates can directly trace their academic journey to the UC-HBCU program.

 The UC-HBCU Initiative exemplifies how partnerships can advance the UC system’s core mission of teaching, research, and public service. By creating pathways for talented students who might otherwise lack access to premier research opportunities, the program enriches the entire academic community while expanding excellence in STEM representation.

“ACES represents more than just a summer research experience – it’s an investment in the future of STEM fields,” said Dr. Potma. “We look forward to hosting our Summer 2026 participants and are grateful to the UC Office of the President for its partnership and commitment to fostering academic excellence and opportunity.”

As the program prepares for its next cohort, ACES continues to demonstrate that targeted investment in high-achieving HBCU students creates lasting change, building a stronger and more innovative scientific workforce for the future.

Click here to learn more about UC Irvine Beckman Laser Institute & Medical Clinic’s ACES program.

The NIH Venture Program Announces First Awards for the NIOI Initiative

The National Institutes of Health (NIH) Common Fund Venture Program has announced its first awards for the Advancing Non-Invasive Optical Imaging Approaches for Biological Systems (NIOI) initiative. This initiative aims to develop innovative non-invasive or minimally invasive light-based imaging techniques specifically designed to overcome technical barriers to imaging biological tissues particularly the longstanding limitation of imaging where light bounces off tiny particles or uneven surfaces and results in unclear images. Over the three years of the initiative, NIH will fund approximately $14.7 million in research across four awards, pending successful completion of milestones and availability of funds. The NIOI initiative is a collaborative effort between the Common Fund, the National Institute on Drug Abuse (NIDA), and the National Institute of Biomedical Imaging and Bioengineering (NIBIB).

Through the NIOI initiative, researchers will advance next-generation imaging technologies that allow deeper, clearer views inside the body without the need for invasive procedures. These innovations are expected to improve early disease detection, enable more precise health monitoring, and support the development of non-invasive and minimally invasive treatment strategies. The new Venture Program NIOI initiative investigators and their institutions are:

  • Lihong Wang of California Institute of Technology aims to develop the next generation of photoacoustic tomography (PAT), a non-invasive imaging technology that uses light and sound to see deep inside the body with high resolution, focusing on improving breast cancer detection and other clinical applications. (1UG3DA065155)
  • Zhongping Chen of the University of California, Irvine; Song Hu of Washington University; and Guifang Li of the University of Central Florida intend to design a fast, advanced imaging system that uses special light techniques to see deep inside living tissues in real-time with clear detail, helping scientists study how the body works and diseases develop. (1UG3DA065120)
  • Tulio Valdez of Stanford University and Ellen Sletten of University of California, Los Angeles, plan to develop a real-time, high-resolution imaging system that enables deep tissue imaging and provides detailed molecular information based on how light interacts with tissue and next generation short-wave infrared imaging (SWIR) molecular probes, which are special dyes that glow when excited with light. (1UG3DA065140)
  • Florian Willomitzer and Clara Curiel-Lewandrowski of the University of Arizona aim to create a new imaging method based on Synthetic Wavelength Imaging (SWI) to non-invasively see skin cancers more clearly and deeply than current techniques, with potential for future use in other deep-tissue imaging applications. (1UG3DA065139)

The Venture Program NIOI initiative is one of two Venture Program initiatives launching in 2025. The second initiative, Newborn Screening by Whole Genome Sequencing (NBSxWGS) Collaboratory, will test the feasibility of a multi-state newborn screening model using whole genome sequencing to identify a targeted set of genetic conditions early in life. The goal is to allow for timely interventions that can dramatically improve health outcomes.

Both initiatives have the potential for outsized impact on biomedical science and are responsive to the shared priorities of NIH Institutes, Centers, and the Office of the Director. In addition, these initiatives emphasize brief, modest investments that can be implemented swiftly in response to emerging opportunities, with a strong potential to accelerate science quickly.

Click here to read the full NIH announcement.

 

UC Irvine team receives $3 million NIH award for revolutionary deep tissue imaging

Funding backs four-university research effort to solve perennial issue of light scattering

Irvine, Calif., Sept. 24, 2025 — A multidisciplinary research team led by the University of California, Irvine has been awarded a prestigious $3 million grant from the National Institutes of Health Common Fund’s Venture Program to develop a revolutionary optical imaging system capable of seeing deep inside living tissues with unprecedented resolution and speed.

The award is part of the NIH’s new Advancing Non-Invasive Optical Imaging Approaches for Biological Systemsinitiative, which seeks to overcome the longstanding physical barrier of light scattering – where light bounces off tiny particles in tissue, resulting in blurry, unclear images. UC Irvine is one of only four institutions nationwide to receive this highly competitive funding, which supports groundbreaking, high-impact research aimed at solving critical biomedical challenges.

The UC Irvine-led project, titled “Breaking the Scattering Barrier: Multimodal Non-Invasive Deep Tissue Imaging Using Reflection Matrix-Based Wavefront Shaping,” will receive $1.5 million annually for two years. There’s also the possibility of a third-year extension, dependent upon the achievement of specific milestones. This groundbreaking technology the team is developing has the potential to revolutionize real-time, noninvasive visualization of dynamic biological processes, with wide-ranging applications in neuroscience, cancer research and cardiovascular disease.

“This award from the NIH is a powerful validation of the transformative science happening at UC Irvine,” said Aileen Anderson, the university’s vice chancellor for research. “It recognizes our researchers’ commitment to pioneering technologies that can rapidly transition from the lab to real-world health applications. We are incredibly proud to be at the forefront of this national initiative.”

The project’s principal investigator is Zhongping Chen, UC Irvine professor of biomedical engineering. He is joined by Fei Xia, assistant professor of electrical engineering and computer science at UC Irvine, Song Hu of Washington University in St. Louis, and Guifang Li of the University of Central Florida.

“For decades, the scattering of light has been a fundamental barrier to seeing deep into living tissue with clarity,” Chen said. “Our goal is to break through this barrier. We are developing a fast, advanced imaging system that uses innovative light techniques to see deep inside the body in clear detail, in real time. This will allow scientists to study how the brain functions, how tumors grow and how the cardiovascular system behaves in ways that were previously impossible, dramatically accelerating the development of new therapies.”

The NIH Common Fund’s Venture Program is designed to catalyze rapid, innovative scientific discovery. The Advancing Non-Invasive Optical Imaging Approaches for Biological Systems initiative is a collaborative effort of the Common Fund, the National Institute on Drug Abuse, and the National Institute of Biomedical Imaging and Bioengineering. In total, NIH will fund approximately $14.7 million in research across the four participating institutions.

The award was made possible, in part, by seed funding from the UC Irvine Office of the Vice Chancellor for Research, which provided critical early support for the project’s development.

About the University of California, Irvine: Founded in 1965, UC Irvine is a member of the prestigious Association of American Universities and is ranked among the nation’s top 10 public universities by U.S. News & World Report. The campus has produced five Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UC Irvine has more than 36,000 students and offers 224 degree programs. It’s located in one of the world’s safest and most economically vibrant communities and is Orange County’s second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide. For more on UC Irvine, visit www.uci.edu.

About the NIH Common Fund: The NIH Common Fund encourages collaboration and supports a series of exceptionally high-impact, trans-NIH programs. These are managed by the Office of Strategic Coordination in the Division of Program Coordination, Planning and Strategic Initiatives within the NIH Office of the Director. More information is available at https://commonfund.nih.gov.

Media access: Radio programs/stations may, for a fee, use an on-campus studio with a Comrex IP audio codec to interview UC Irvine faculty and experts, subject to availability and university approval. For more UC Irvine news, visit news.uci.edu. Additional resources for journalists may be found at https://news.uci.edu/media-resources.

Click here to read full press release.

Chen and Xia Secure Prestigious NIH Common Fund Venture Program Grant to Develop Groundbreaking Noninvasive Deep Tissue Imaging System

UC Irvine Beckman Laser Institute & Medical Clinic’s Drs. Zhongping Chen and Fei Xia have been selected as one of only four national research teams to receive the prestigious National Institutes of Health (NIH) Common Fund Venture Program grant.

Their project, “Breaking the Scattering Barrier: Multimodal Noninvasive Deep Tissue Imaging Using Reflection Matrix Based Wavefront Shaping,” aims to develop revolutionary optical imaging technology capable of seeing deep inside living tissues with unprecedented resolution and depth.

Working in collaboration with Dr. Song Hu of Washington University and Dr. Guifang Li of University of Central Florida, Drs. Chen and Xia are developing a high-speed, multimodal deep tissue imaging system.  This innovative system integrates reflection matrix optical coherence tomography (RM-OCT) with wavefront shaping to overcome the fundamental limitations caused by light scattering in biological tissues.

By overcoming the fundamental scattering barrier of light, this technology will enable real-time, noninvasive visualization of dynamic biological processes. This breakthrough has broad applications in neuroscience, cancer research, and cardiovascular disease, and is poised to accelerate the development of new therapeutic approaches.

The NIH Common Fund Venture Program award provides $1.5 million annually over two years, with the potential for milestone-based funding in a third year. This award recognizes the team’s bold approach to creating practical, novel, and transformative technologies that can be rapidly applied in health-relevant applications.

The NIH Common Fund Venture Program specifically supports fast-paced, high-impact research that addresses critical biomedical challenges. The program embraces bold approaches and responds to the shared priorities of NIH Institutes, Centers, and the Office of the Director.

Click here to learn more about the NIH Common Fund Venture Program.

Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number UG3DA065120. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

 

Shining light on trauma care

UC Irvine laser scientists pioneer optical technologies to save lives on the battlefield and beyond

When someone suffers a devastating injury – whether from a roadside blast, a car accident or a house fire – seconds matter. Doctors need to know instantly what damage has been done and how best to treat it. At UC Irvine’s Beckman Laser Institute & Medical Clinic, researchers are developing new tools to give physicians exactly that kind of real-time insight – using beams of light.

Thanks to a $7.2 million grant from the U.S. Department of Defense’s Air Force Office of Scientific Research, a team led by biomedical engineering professor Bernard Choi, acting BLI director, is pushing the boundaries of what’s possible in trauma medicine. The three-year initiative, officially titled “Advanced Optical Technologies for Defense Trauma and Critical Care,” spans six interconnected projects. Together, they aim to bring light-based diagnostics and therapies out of the lab and into the hands of doctors treating the most urgent cases.

A 30-year evolution

The Defense Department’s investment in medical photonics isn’t new. It stretches back more than three decades, when BLI founder and seminal biological and laser researcher Michael Berns helped pioneer the Medical Free Electron Laser Program in the early 1990s. Originally focused on how high-powered lasers interacted with tissue, the program has since evolved into today’s Military Medical Photonics Program, with an emphasis on trauma and critical care.

What’s different now is the urgency and practicality. The projects under Choi’s leadership are designed not just for theoretical advances, but to solve “DoD-defined medical technology gaps” on the battlefield – needs that often mirror challenges in civilian hospitals.

Lighting the way in trauma medicine

The six projects under the current center grant cover a wide range of medical crises:

  • Airway injuries from smoke or toxic gas inhalation, where high-speed optical imaging can detect early signs of injury and monitor therapy deep in the airways.
  • Burns from thermal, radiation, and directed energy exposure, where light can help assess severity and guide very early treatment.
  • Hemorrhagic shock, a life-threatening condition when blood loss pushes the body toward collapse. Optical sensors could allow doctors to detect it before it becomes irreversible.
  • Lactate acid, a metabolic indicator of severity of injury, can be continuously monitored by a miniature light-based sensor to assess a patient’s condition, need for critical support and response to treatment.
  • Traumatic brain injury, where monitoring blood flow in the brain can inform lifesaving interventions.
  • Compartment syndrome, a painful swelling in the limbs after injury that can cut off circulation and seriously injure muscle function—detected noninvasively using light.
  • Compact field-deployable laser surgical device for debridement of complex soft tissue wounds.

“The goal is to give clinicians fast, accurate, and noninvasive ways to see what’s happening inside the body during trauma care,” Choi says. “That benefits not only military medicine but civilian patients as well.”

From lab to real life

Not all of these technologies are years away from application. Some are already making their way into hospitals. One standout is Spatial Frequency Domain Imaging, a technique that maps tissue health using patterns of projected light. SFDI has been commercialized through Modulim, a Costa Mesa-based medical technology company that grew directly out of Beckman Laser Institute research.

Today, Modulim’s devices are being used to monitor tissue health in patients with diabetes and vascular disease, helping prevent dangerous ulcers and amputations. It’s a prime example of how defense-funded research can translate into tools that improve everyday healthcare.

The bigger picture

For Choi and his team, the progress is steady and encouraging. “We keep making progress, and the Defense Health Agency seems to be pleased with our work,” he says.

Ultimately, the promise of optical technology is its ability to deliver quick, precise, and actionable data – without invasive procedures. Whether on the front lines of combat or in the emergency room of a community hospital, that information can mean the difference between life and death.

What started as an exploration of powerful lasers decades ago is now reshaping the future of trauma medicine. With continued support from the Department of Defense and partnerships with industry, UC Irvine’s scientists are proving that sometimes, the best way to heal is to shine a light.

Generative AI assisted in the writing of this story.

Click here to read full story on UC Irvine News.

UC Irvine Researcher Receives Grant to Combat Vision-Threatening Eye Disease

Dr. Lilangi Ediriwickrema awarded K23 grant to develop breakthrough imaging technology for thyroid eye disease

Dr. Lilangi Ediriwickrema, a UCI Health ophthalmologist at the Gavin Herbert Eye Institute, has been awarded a competitive K23 grant from the National Eye Institute to revolutionize how doctors diagnose and treat thyroid eye disease (TED). Her groundbreaking project, “Spatial Frequency Domain Imaging to Investigate Mechanistic Constituents in Active Thyroid Eye Disease,” could transform care for hundreds of thousands of patients worldwide.

A Disease That Goes Beyond Vision

Thyroid eye disease affects an estimated 90 to 300 per 100,000 people globally, with some sources citing up to half a million cases in the U.S. alone. Most commonly linked to Graves’ Disease, TED occurs when the immune system mistakenly attacks muscle and fat tissue behind the eyes, causing devastating symptoms including painful, bulging eyes; blurry or double vision; persistent eye pressure and irritation and inflammation and swelling.

“Moderate to severe thyroid eye disease can also be socially stigmatizing, affecting patients beyond their clinical symptoms,” explains Dr. Ediriwickrema, who serves as an assistant professor in UC Irvine School of Medicine’s Department of Ophthalmology. The condition can profoundly impact patients’ quality of life, self-esteem, and social interactions.

Pioneering Non-Invasive Technology

Dr. Ediriwickrema’s innovative approach uses Spatial Frequency Domain Imaging—a cutting-edge, non-invasive technique—to identify specific optical tissue properties in TED patients. By comparing these findings with age-matched healthy controls, her research aims to pinpoint key disease markers, particularly those related to vascular congestion and tissue swelling.

The research team will also analyze surgical specimens from both healthy individuals and TED patients to validate their imaging findings. This comprehensive approach could lead to earlier, more accurate diagnosis; better monitoring of treatment response; and improved therapeutic options for patients.

“The treatment landscape is continually evolving,” Dr. Ediriwickrema notes optimistically. “We hope that in the next 10 to 20 years we can offer patients even more options to manage this disease.”

Building Tomorrow’s Medical Leaders

The K23 award specifically supports early-career clinician-scientists like Dr. Ediriwickrema in developing independent patient-oriented research careers. Working under the guidance of mentors Drs. Bernard Choi, Anthony Durkin, and Anand Ganesan, she represents the next generation of physician-researchers tackling complex medical challenges.

This funding mechanism emphasizes patient-oriented research—studies that directly involve human subjects or their biological materials—ensuring that laboratory discoveries translate into real-world medical advances.

About the National Eye Institute (NEI)

The National Eye Institute (NEI) leads the federal government’s efforts to eliminate vision loss and improve quality of life through vision research, including driving innovation, fostering collaboration, expanding the vision workforce, and educating the public and key stakeholders. The NEI supports basic and clinical science programs to develop sight-saving treatments and to broaden opportunities for people with vision impairment.  For more information, visit   https://www.nei.nih.gov.

About the National Institutes of Health (NIH)

The National Institutes of Health (NIH), the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.